Synonym
LSP1-2111; LSP1 2111; LSP12111.
IUPAC/Chemical Name
(2S)-2-amino-4-{hydroxy[hydroxy(4-hydroxy-3-methoxy-5-nitrophenyl)methyl]phosphoryl}butanoic acid
InChi Key
PEXVMHLARUAHNC-KAJCPDDVSA-N
InChi Code
InChI=1S/C12H17N2O9P/c1-23-9-5-6(4-8(10(9)15)14(19)20)12(18)24(21,22)3-2-7(13)11(16)17/h4-5,7,12,15,18H,2-3,13H2,1H3,(H,16,17)(H,21,22)/t7-,12?/m0/s1
SMILES Code
O=C(O)[C@@H](N)CCP(C(O)C1=CC([N+]([O-])=O)=C(O)C(OC)=C1)(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
364.25
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Cajina M, Nattini M, Song D, Smagin G, Jørgensen EB, Chandrasena G, Bundgaard C, Toft DB, Huang X, Acher F, Doller D. Qualification of LSP1-2111 as a Brain Penetrant Group III Metabotropic Glutamate Receptor Orthosteric Agonist. ACS Med Chem Lett. 2013 Dec 12;5(2):119-23. doi: 10.1021/ml400338f. PubMed PMID: 24900783; PubMed Central PMCID: PMC4027608.
2: Wierońska JM, Acher FC, Sławińska A, Gruca P, Lasoń-Tyburkiewicz M, Papp M, Pilc A. The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT₁A signalling. Psychopharmacology (Berl). 2013 Jun;227(4):711-25. doi: 10.1007/s00213-013-3005-0. PubMed PMID: 23474845; PubMed Central PMCID: PMC3663209.
3: Wierońska JM, Stachowicz K, Acher F, Lech T, Pilc A. Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia. Psychopharmacology (Berl). 2012 Apr;220(3):481-94. doi: 10.1007/s00213-011-2502-2. PubMed PMID: 21952670; PubMed Central PMCID: PMC3299972.
4: Wierońska JM, Stachowicz K, Pałucha-Poniewiera A, Acher F, Brański P, Pilc A. Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems. Neuropharmacology. 2010 Dec;59(7-8):627-34. doi: 10.1016/j.neuropharm.2010.08.008. PubMed PMID: 20713068.
